Clovis Lung Cancer Drug Study Shows Ups and Downs of Trials

  • Mature data shows 45 percent of patients improved on treatment
  • Researchers say more data needed to clarify rociletinib's role

Researchers who led a trial of Clovis Oncology Inc.’s experimental lung cancer drug, which is likely to be rejected next month by U.S. regulators, updated results from tests of the treatment after they said initial, promising data from the clinical trial were hurried out last year.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.